Cargando…

The HDAC Inhibitor Vorinostat Diminishes the In Vitro Metastatic Behavior of Osteosarcoma Cells

Osteosarcoma (OS) is the most common primary malignancy of bone and affects patients in the first two decades of life. The greatest determinant of survival is the presence of pulmonary metastatic disease. The role of epigenetic regulation in OS, specifically the biology of metastases, is unknown. Ou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mu, Xiaodong, Brynien, Daniel, Weiss, Kurt R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4346695/ https://www.ncbi.nlm.nih.gov/pubmed/25785263 http://dx.doi.org/10.1155/2015/290368

Ejemplares similares

Crafting Carbazole-Based Vorinostat and Tubastatin-A-like Histone Deacetylase (HDAC) Inhibitors with Potent in Vitro and in Vivo Neuroactive Functions
por: Reddy, R. Gajendra, et al.
Publicado: (2019)

Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo
por: Hrzenjak, Andelko, et al.
Publicado: (2010)

Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy
por: Park, Haeseong, et al.
Publicado: (2016)

Notch Signaling is Associated with ALDH Activity and an Aggressive Metastatic Phenotype in Murine Osteosarcoma Cells
por: Mu, Xiaodong, et al.
Publicado: (2013)

Role of 5′TG3′-interacting factors (TGIFs) in Vorinostat (HDAC inhibitor)-mediated Corneal Fibrosis Inhibition
por: Sharma, Ajay, et al.
Publicado: (2015)

Rapamycin Inhibits ALDH Activity, Resistance to Oxidative Stress, and Metastatic Potential in Murine Osteosarcoma Cells
por: Mu, Xiaodong, et al.
Publicado: (2013)

Retinal Targets ALDH Positive Cancer Stem Cell and Alters the Phenotype of Highly Metastatic Osteosarcoma Cells
por: Mu, Xiaodong, et al.
Publicado: (2015)

Design, synthesis and biological evaluation of VEGFR-2/HDAC dual inhibitors as multitargeted antitumor agents based on fruquintinib and vorinostat
por: Gao, Yali, et al.
Publicado: (2023)

HR23b expression is a potential predictive biomarker for HDAC inhibitor treatment in mesenchymal tumours and is associated with response to vorinostat
por: Angelika Ihle, Michaela, et al.
Publicado: (2016)

Vorinostat—An Overview
por: Bubna, Aditya Kumar
Publicado: (2015)

A G-Quadruplex-Binding Small Molecule and the HDAC Inhibitor SAHA (Vorinostat) Act Synergistically in Gemcitabine-Sensitive and Resistant Pancreatic Cancer Cells †
por: Ahmed, Ahmed Abdullah, et al.
Publicado: (2020)

Effect of vorinostat on INK4 family and HDACs 1, 2, and 3 in pancreatic cancer and hepatocellular carcinoma
por: Sanaei, Masumeh, et al.
Publicado: (2021)

Phospholipase D1 is upregulated by vorinostat and confers resistance to vorinostat in glioblastoma
por: Kang, Dong Woo, et al.
Publicado: (2020)

Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis
por: Murahari, Sridhar, et al.
Publicado: (2017)

The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo
por: Chao, Min-Wu, et al.
Publicado: (2015)

Evaluation of the Antitumor Effects of BPR1J-340, a Potent and Selective FLT3 Inhibitor, Alone or in Combination with an HDAC Inhibitor, Vorinostat, in AML Cancer
por: Lin, Wen-Hsing, et al.
Publicado: (2014)

Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer
por: Patel, Sukeshi, et al.
Publicado: (2016)

Improved HDAC Inhibition, Stronger Cytotoxic Effect and Higher Selectivity against Leukemias and Lymphomas of Novel, Tricyclic Vorinostat Analogues
por: Bieszczad, Bartosz, et al.
Publicado: (2021)

HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A
por: Juengel, Eva, et al.
Publicado: (2014)

Vorinostat in solid and hematologic malignancies
por: Siegel, David, et al.
Publicado: (2009)

Differential Response of Mycosis Fungoides Cells to Vorinostat
por: Bordeaux, Zachary A., et al.
Publicado: (2023)

Anti-tumor effects of the histone deacetylase inhibitor vorinostat on canine urothelial carcinoma cells
por: Eto, Shotaro, et al.
Publicado: (2019)

Antioxidants Impair Anti-Tumoral Effects of Vorinostat, but Not Anti-Neoplastic Effects of Vorinostat and Caspase-8 Downregulation
por: Bergadà, Laura, et al.
Publicado: (2014)

Genistein cooperates with the histone deacetylase inhibitor vorinostat to induce cell death in prostate cancer cells
por: Phillip, Cornel J, et al.
Publicado: (2012)

Vorinostat (SAHA) and Breast Cancer: An Overview
por: Wawruszak, Anna, et al.
Publicado: (2021)

Effect of histone deacetylase inhibitor (vorinostat) on new-onset diabetes induced by tacrolimus
por: Bakhdar, Fatmah A., et al.
Publicado: (2022)

A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma
por: Goncalves, Priscila H., et al.
Publicado: (2017)

Brief Report: Case Comparison of Therapy With the Histone Deacetylase Inhibitor Vorinostat in a Neonatal Calf Model of Pulmonary Hypertension
por: Applegate, Tanya J., et al.
Publicado: (2021)

Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma
por: Saelen, Marie Grøn, et al.
Publicado: (2012)

Co-Prodrugs of 7-Ethyl-10-hydroxycamptothecin and Vorinostat with in Vitro Hydrolysis and Anticancer Effects
por: Liu, Shuangxi, et al.
Publicado: (2019)

Clinical Efficacy of Vorinostat in a Patient with Leiomyosarcoma
por: Lee, Jin, et al.
Publicado: (2012)

The Effect of Vorinostat on the Development of Resistance to Doxorubicin in Neuroblastoma
por: Lautz, Timothy B., et al.
Publicado: (2012)

Immune effectors required for the therapeutic activity of vorinostat
por: Kepp, Oliver, et al.
Publicado: (2013)

Notch Signaling Mediates Skeletal Muscle Atrophy in Cancer Cachexia Caused by Osteosarcoma
por: Mu, Xiaodong, et al.
Publicado: (2016)

Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat
por: Duvic, Madeleine, et al.
Publicado: (2007)

Vorinostat enhances the anticancer effect of oxaliplatin on hepatocellular carcinoma cells
por: Liao, Bo, et al.
Publicado: (2017)

Fluvastatin potentiates anticancer activity of vorinostat in renal cancer cells
por: Okubo, Kazuki, et al.
Publicado: (2019)

The relationship between metastatic potential and in vitro mechanical properties of osteosarcoma cells
por: Holenstein, Claude N., et al.
Publicado: (2019)

HDAC class I inhibitor, Mocetinostat, reverses cardiac fibrosis in heart failure and diminishes CD90+ cardiac myofibroblast activation
por: Nural-Guvener, Hikmet F, et al.
Publicado: (2014)

Improved Anticancer Activities of a New Pentafluorothio-Substituted Vorinostat-Type Histone Deacetylase Inhibitor
por: Goehringer, Nils, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4534ehbis9qun36atpm75kcdg6